目的 探討復(fù)方夏天無(wú)片聯(lián)合艾拉莫德治療類風(fēng)濕關(guān)節(jié)炎患者的臨床療效。方法 選取2022年2月—2024年2月武漢市中醫(yī)醫(yī)院收治的106例類風(fēng)濕關(guān)節(jié)炎患者，隨機(jī)分為對(duì)照組（53例）和治療組（53例）。對(duì)照組患者口服艾拉莫德片，25 mg/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服復(fù)方夏天無(wú)片，4片/次，3次/d。兩組患者用藥10周。觀察兩組患者臨床療效，比較治療前后兩組患者炎性因子Ⅱ型膠原C端肽（CTX-Ⅱ）、白三烯B4（LTB4）、P物質(zhì)（SP）和白細(xì)胞介素-1β（IL-1β）水平，關(guān)節(jié)疾病活動(dòng)度（DAS-28）評(píng)分和視覺(jué)模擬疼痛評(píng)分（VAS），及類風(fēng)濕因子血沉（ESR）、類風(fēng)濕因子（RF）、抗環(huán)瓜氨酸肽抗體（CCP）和C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組臨床總有效率（96.23%）明顯高于對(duì)照組（83.02%）。治療后，兩組DAS-28評(píng)分、VAS評(píng)分均明顯低于治療前（P＜0.05），且治療組DAS-28評(píng)分、VAS評(píng)分明顯低于對(duì)照組（P＜0.05）。治療后，兩組患者CTX-Ⅱ、LTB4、SP、IL-1β、ESR、RF、CCP、CRP水平明顯降低（P＜0.05），且治療組這些指標(biāo)水平均明顯低于對(duì)照組（P＜0.05）。結(jié)論 復(fù)方夏天無(wú)片聯(lián)合艾拉莫德治療類風(fēng)濕關(guān)節(jié)炎療效確切，可對(duì)關(guān)節(jié)腫脹、疼痛等癥狀較好的改善，并能增加關(guān)節(jié)血流，促使關(guān)節(jié)恢復(fù)到穩(wěn)定狀態(tài)。

Objective To explore the clinical efficacy of Compound Xiatianwu Tablets combined with iguratimod in treatment of rheumatoid arthritis. Methods Patients (106 cases) with rheumatoid arthritis in Wuhan Hospital of Traditional Chinese Medicine from February 2022 to February 2024 were randomly divided into control (53 cases) and treatment (53 cases) group. Patients in the control group were po administered with Iguratimod Tablets, 25 mg/time, twice daily. Patients in the treatment group were po administered with Compound Xiatianwu Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 10 weeks. After treatment, the clinical evaluations were evaluated, the scores of DAS-28 and VAS, the levels of CTX-Ⅱ, LTB4, SP, IL-1β, ESR, RF, CCP and CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 96.23% significantly higher than 83.02% in the control group (P < 0.05). After treatment, the DAS-28 scores and VAS scores in two groups were significantly lower than before treatment (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of CTX-Ⅱ, LTB4, SP, IL-1β, ESR, RF, CCP, and CRP in two groups were significantly reduced (P < 0.05), and the levels of these indicators in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The combination of iguratimod and Compound Xiatianwu Tablets in treatment of patients with rheumatoid arthritis has a definite effect. It can improve joint swelling, pain and other symptoms, increase joint blood flow, and promote the joint to return to a stable state.

R982

湖北省科學(xué)技術(shù)廳資助項(xiàng)目(2018CFB707)